Method and compositions comprising a CT20 peptide
US-11129868-B2 · Sep 28, 2021 · US
Methods and compositions for theranostic nanoparticles
US12097264B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12097264-B2 |
| Application number | US-202117228286-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 12, 2021 |
| Priority date | Apr 28, 2015 |
| Publication date | Sep 24, 2024 |
| Grant date | Sep 24, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein is a nanoparticle for drug delivery, wherein the nanoparticle comprises a hyperbranched polyester (HBPE) nanoparticle having a hydrophobic interior, polyglutamate folate ligands conjugated to the nanoparticle, and one or more PET detectable isotopes. Also provided herein are methods of using thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A nanoparticle for drug delivery, comprising: a hyperbranched polyester (HBPE) nanoparticle having a hydrophobic interior, polyglutamate folate ligands conjugated to the nanoparticle, one or more PET detectable isotopes, and a therapeutic agent, wherein the therapeutic agent is an anti-metastatic agent, antiandrogenic agent, anti-neoplastic agent, or a radiosensitizer. 2. The nanoparticle of claim 1 , wherein the therapeutic agent is the anti-metastatic agent. 3. The nanoparticle of claim 1 , wherein the therapeutic agent is the antiandrogenic agent. 4. The nanoparticle of claim 1 , wherein the therapeutic agent is the anti-neoplastic agent. 5. The nanoparticle of claim 1 , wherein the therapeutic agent is the radiosensitizer. 6. The nanoparticle of claim 1 , wherein the nanoparticle comprises desferrioxamine (DFO). 7. The nanoparticle of claim 1 , wherein the PET detectable isotope is 89 Zr or 64 Cu. 8. The nanoparticle of claim 1 , wherein the nanoparticle further comprises PEG. 9. A method of administering a therapeutic agent to a subject, comprising: administering to the cancer subject the nanoparticle of claim 1 .
Assignees
Inventors
Classifications
the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol · CPC title
Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title
the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12097264B2 cover?
- Provided herein is a nanoparticle for drug delivery, wherein the nanoparticle comprises a hyperbranched polyester (HBPE) nanoparticle having a hydrophobic interior, polyglutamate folate ligands conjugated to the nanoparticle, and one or more PET detectable isotopes. Also provided herein are methods of using thereof.
- Who is the assignee on this patent?
- Univ Central Florida Res Found Inc, Sanford Burnham Prebys Medical Discovery Inst At Lake Nona, Memorial Sloan Kettering Cancer Center, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/6869. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).